Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Gastrointestinal stromal tumor: a clinical overview.

Quek R, George S.

Hematol Oncol Clin North Am. 2009 Feb;23(1):69-78, viii. doi: 10.1016/j.hoc.2008.11.006. Review.

PMID:
19248971
2.

[Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].

Mac K, Wójcik M.

Postepy Hig Med Dosw (Online). 2007 Jun 9;62:272-81. Review. Polish.

3.

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.

Anticancer Drugs. 2008 Jul;19(6):607-12. doi: 10.1097/CAD.0b013e32830138f9.

PMID:
18525320
4.

Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models.

Antonescu CR.

Semin Diagn Pathol. 2006 May;23(2):63-9. Review.

PMID:
17193819
5.

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.

Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.

Scand J Gastroenterol. 2009;44(6):760-3. doi: 10.1080/00365520802647459.

PMID:
19096980
6.

Current management of GIST.

Blanke C.

Clin Adv Hematol Oncol. 2004 May;2(5):280, 283. No abstract available.

PMID:
17682286
7.

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.

Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.

Am J Surg Pathol. 2009 Feb;33(2):218-26. doi: 10.1097/PAS.0b013e31817ec2e6.

PMID:
18830121
8.

[The role of the pathologist in the management of gastrointestinal stromal tumors (GIST)].

Bouzourene H.

Rev Med Suisse. 2009 Jul 15;5(211):1505-8. French.

PMID:
19694360
9.

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.

Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S.

Cancer Sci. 2008 Apr;99(4):799-804. doi: 10.1111/j.1349-7006.2008.00727.x. Epub 2008 Feb 21.

10.

Gastrointestinal stromal tumors (GISTs): a pathology view point.

Sornmayura P.

J Med Assoc Thai. 2009 Jan;92(1):124-35. Review.

PMID:
19260254
11.

Targeted therapies in gastrointestinal stromal tumors.

Antonescu CR.

Semin Diagn Pathol. 2008 Nov;25(4):295-303. Review.

PMID:
19013895
12.

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

Sakurama K, Noma K, Takaoka M, Tomono Y, Watanabe N, Hatakeyama S, Ohmori O, Hirota S, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tanaka N, Naomoto Y.

Mol Cancer Ther. 2009 Jan;8(1):127-34. doi: 10.1158/1535-7163.MCT-08-0884.

13.

Multidisciplinary treatment of gastrointestinal stromal tumors.

Kingham TP, DeMatteo RP.

Surg Clin North Am. 2009 Feb;89(1):217-33, x. doi: 10.1016/j.suc.2008.10.003. Review.

PMID:
19186237
14.

Gastric GISTs. Personal experience.

Mingolla GP, Riccio PA, Linguerri R, La Donna M, Zannelli M, Artuso S.

Ann Ital Chir. 2007 Jul-Aug;78(4):283-8; discussion 288-9.

PMID:
17990602
15.

Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.

Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A.

Semin Oncol. 2009 Aug;36(4):302-11. doi: 10.1053/j.seminoncol.2009.06.003.

PMID:
19664491
16.

[Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors].

Belev B, Vrbanec D, Kralik M, Plestina S, Petricević B, Sirotković-Skerlev M.

Acta Med Croatica. 2006 Dec;60(5):471-5. Review. Croatian.

PMID:
17217104
17.

[Expression of MDR1 and KIT in imatinib-resistant gastrointestinal stromal tumor cells].

Liu JL, Qin J, Yao LQ, Hou YY, Sun YH, Shen KT, Su P.

Zhonghua Wei Chang Wai Ke Za Zhi. 2010 Jul;13(7):506-9. Chinese.

PMID:
20658364
18.

Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.

Loughrey MB, Waring PM, Dobrovic A, Demetri G, Kovalenko S, McArthur G.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6205-6; author reply 6206-7. No abstract available.

19.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738
20.

Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.

Judson IR.

J Clin Oncol. 2008 Nov 20;26(33):5322-5. doi: 10.1200/JCO.2008.17.7725. Epub 2008 Oct 27. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk